References
- 1. KUBIAK A, NIEMIR ZI. [The role of podocytes in normal glomerular function and in the pathogenesis of glomerulonephritis. Part I. Phenotypic and functional characteristics of podocytes during their differentiation and maturity]. Postepy Hig Med Dosw (Online). 2006;60:248–58.
- 2. SNYDER KA, HUGHES MR, HEDBERG B, BRANDON J, HERNAEZ DC, BERGQVIST P, et al. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Res. 2015;17(1):46.
- 3. KELLEY TW, HUNTSMAN D, MCNAGNY KM, ROSKELLEY CD, HSI ED. Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol. 2005;124(1):134–42.
- 4. SCHOPPERLE WM, KERSHAW DB, DEWOLF WC. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun. 2003;300(2):285–90.
- 5. HARA M, YAMAMOTO T, YANAGIHARA T, TAKADA T, ITOH M, ADACHI Y, et al. Urinary excretion of podocalyxin indicates glomerular epithelial cell injuries in glomerulonephritis. Nephron. 1995;69(4):397–403.
- 6. NIELSEN JS, MCNAGNY KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009;20(8):1669–76.
- 7. CHEN Q, WANG Y, LI Y, ZHAO M, NIE G. Serum podocalyxin is significantly increased in early-onset preeclampsia and may represent a novel marker of maternal endothelial cell dysfunction. J Hypertens. 2017;35(11):2287–94.
- 8. NAKAMURA T, USHIYAMA C, SUZUKI S, HARA M, SHIMADA N, EBIHARA I, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15(9):1379–83.
- 9. PALACIOS DE FRANCO Y, VELAZQUEZ K, SEGOVIA N, ACOSTA C, YANOSKY D, FRANCO PALACIOS YV, et al. Urinary podocalyxin as a marker of preeclampsia in a Hispanic population. Int J Physiol Pathophysiol Pharmacol. 2014;6(2):115–24.
- 10. CRAICI IM, WAGNER SJ, BAILEY KR, FITZ-GIBBON PD, WOOD-WENTZ CM, TURNER ST, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension. 2013;61(6):1289–96.
- 11. ZHAI T, FURUTA I, AKAISHI R, ISHIKAWA S, MORIKAWA M, YAMADA T, et al. Alteration of podocyte phenotype in the urine of women with preeclampsia. Sci Rep. 2016;6:24258.
- 12. TANAMAI VW, SEAGLE BL, YEH JY, BRADY B, MILLER CB, SENA S, et al. Urine Protein/Creatinine Ratios during Labor: A Prospective Observational Study. PLoS One. 2016;11(8):e0160453.
- 13. PALACIOS DE FRANCO Y, VELAZQUEZ K, SEGOVIA N, SANDOVAL G, GAUTO E, FRANCO PALACIOS YV, et al. Long term follow up of biomarkers of podocyte damage and renal function in patients with and without preeclampsia. J Bras Nefrol. 2018;40(4):339–43.
- 14. KOSTOVSKA I, TRAJKOVSKA KT, CEKOVSKA S, TOPUZOVSKA S, KAVRAKOVA JB, SPASOVSKI G, et al. Role of urinary podocalyxin in early diagnosis of diabetic nephropathy. Rom J Intern Med. 2020;58(4):233–41.
- 15. AIROLDI J, WEINSTEIN L. Clinical significance of proteinuria in pregnancy. Obstet Gynecol Surv. 2007;62(2):117–24.
- 16. TATENO H, MATSUSHIMA A, HIEMORI K, ONUMA Y, ITO Y, HASEHIRA K, et al. Podocalyxin is a glycoprotein ligand of the human pluripotent stem cell-specific probe rBC2LCN. Stem Cells Transl Med. 2013;2(4):265–73.
- 17. ROBERTS M, LINDHEIMER MD, DAVISON JM. Altered glomerular permselectivity to neutral dextrans and heteroporous membrane modeling in human pregnancy. Am J Physiol. 1996;270(2 Pt 2):F338–43.